Sotuvning sof marjinal rentabelligi: Erasca Corp (ERAS)

Erasca Corp (ERAS) tovar belgisi

Erasca, Inc. (ERAS) dori ishlab chiqarishni tashqi pudratchilarga topshirish orqali aktivlarga kamroq bog'langan modeldan foydalanadi. Klinik sinovlarning muvaffaqiyatsiz tugash xavflari yetarli likvidlik bilan qoplanadi. GURU.Markets platformasida real marjalar xarajatlar samaradorligini ko'rsatmoqda, bunda joriy ko'rsatkich 0.00 darajasida turibdi. O'sish istiqbollari maqsadli RAS/MAPK yo'nalishidagi terapiyalarni ishlab chiqish va sog'liqni saqlash gigantlari bilan strategik hamkorlikka asoslangan.

erasca.com (ERAS) - Sotuvning sof marjinal rentabelligi 04.07.2022dan 19.11.2026gacha

Erasca Oncology (ERAS) boʻyicha maʼlumotlarning jamlanma tahliliy kesimlari

- bozor qiymati va tahlilchilarning maqsadli prognozi:
Kompaniyaning jamlanma tahlili:Erasca Inc - ERAS
Erasca Corp yetakchi tovari

Klinik sinovlar bosqichida bo'lgan Erasca, Inc. (ERAS) ventur biznesi uchun savdo marjasi tijorat daromadlari mavjud bo'lmagan holatda operatsion barqarorlikning ko'rsatkichi bo'lib xizmat qiladi. Ushbu sof savdo rentabelligi doirasida daromad birligiga to'g'ri keladigan sof foydaning kunlik hisob-kitobi molekula ishlab chiqish xarajatlari tendentsiyalarini real vaqt rejimida baholash imkonini beradi va dori vositalarini bozorga chiqarishdan oldin yuqori xatarlarga qarshi kapital zaxirasini belgilaydi.

Asosiy raqobatchilar

ONC: Sotuvning sof marjinal rentabelligi|Sof marja Halozyme Inc. (HALO)|Sof marja RevMed|Sotuvning sof rentabelligi AAPG (Ascentage Pharma Group)|Sotuvning sof marjinal rentabelligi CGON|UroGen Pharma - Sotuvning sof rentabelligi|Bicara Therapeutics - Sof foyda bo'yicha sotuv rentabelligi|Sotuvning sof marjinal rentabelligi Personalis Inc PSNL|DCTH: Sof foyda bo'yicha sotuv rentabelligi|YmAbs - Kompaniyaning sof rentabelligi|aurabiosciences.com (AURA) - Sof marja|Candel Therapeutics Inc. - Sof foyda normasi|Sof marja Accuray Inc.|Sof marja SELLAS Life Sciences Group SLS|Sotuvning sof marjinal rentabelligi ACTU|CTOR - Sof marja|Sotuvning sof marjinal rentabelligi HURA (TuHURA Biosciences, Inc.)|Sof foyda normasi TARA|FATE: Sof foyda bo'yicha sotuv rentabelligi|WHWK (aadibio.com) - Sotuvning sof rentabelligi|TCRX (TScan Therapeutics, Inc.) - Sof foyda bo'yicha sotuv rentabelligi|Sof marja Champions Oncology Corp (CSBR)|XBIT (XBiotech Inc.) - Sotuvning sof marjinal rentabelligi|CVM (CEL-SCI Corporation) - Kompaniyaning sof rentabelligi|Sotuvning sof marjinal rentabelligi OSTX|Sotuvning sof marjinal rentabelligi Radiopharm Theranostics Ltd (RADX)|Sotuvning sof marjinal rentabelligi ARTV (Artiva Biotherapeutics)|Sotuvning sof marjinal rentabelligi Adlai Nortye Ltd. ANL|Veru Inc - Sotuvning sof marjinal rentabelligi|Kompaniya sotuv marjasi Tempest Therapeutics TPST|XLO: Sotuvning sof marjinal rentabelligi|Enochian BioSciences (RENB) - Sotuvning sof marjinal rentabelligi|Sof foyda bo'yicha sotuv rentabelligi MURA|Kairos Pharma Ltd - Sof foyda marjasi|Sotuvning sof marjinal rentabelligi OKUR|CytoMed Therapeutics Limited (GDTC) - Sof foyda bo'yicha marjinallik|Sotuvning sof marjinal rentabelligi CRIS (Curis, Inc.)|APLM: Sotuvning sof rentabelligi|Tharimmune Corporation - Sotuvning sof marjinal rentabelligi|ADVB: Sof marja|GNPX: Sotuvning sof marjinal rentabelligi|CLDI (Calidi Biotherapeutics Inc.) - Sof marja|Sof marja Sunshine Biopharma, Inc.|Sotuvning sof marjinal rentabelligi xeneticbio.com|Sof marja Salarius (SLRX)|Sof foyda bo'yicha sotuv rentabelligi Purple Biotech PPBT|Sof marja American Oncology Network, Inc. AONC|BeiGene, Ltd. (BGNE) - Sof marja|Checkpoint Therapeutics Inc. - Sotuvning sof marjinal rentabelligi|Sof foyda normasi ELEV (Elevation Oncology)|ICAD (iCAD Corp) - Sof foyda bo'yicha sotuv rentabelligi|Ikena Oncology, Inc. - Sof foyda normasi|Sof foyda bo'yicha sotuv rentabelligi NTBL|VIRX: Sof foyda normasi|Sof marja MorphoSys Corporation (MOR)|NAYA - Sof marja|Sotuvning sof marjinal rentabelligi AAPGV (Ascentage)